A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
|Articles|January 18, 2022
Israeli Study Finds Fourth COVID-19 Dose Insufficient Against Omicron
Author(s)Nina Cosdon
An Israeli study is the first to administer 4 COVID-19 shots, but the boosted antibodies may still not be enough to prevent Omicron breakthrough infections.
Advertisement
Sheba Medical Center in Israel recently launched the world’s first study of a fourth COVID-19 vaccine dose. Less than a month after the study launched, the investigators reported that the fourth booster offered insufficient protection against the
Dr. Gili Regev-Yochay, director of the Infection Prevention and Control Unit at Sheba Medical Center and one of the study’s lead researchers, said, “The vaccine, which was very effective against the previous strains, is less effective against the Omicron strain… The bottom line is that the vaccine is excellent against the Alpha and Delta, for Omicron it’s not good enough.”
A fourth dose of the mRNA Pfizer-BioNTech or Moderna vaccines boosts antibody levels above the
“We see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections,” Regev-Yochay said. She noted that the study found no significant difference in breakthrough infections between Pfizer-BioNTech and Moderna recipients.
Over 500000 Israelis have received 4 doses of mRNA COVID-19 vaccine. Currently, Israel’s Health Ministry has authorized a fourth shot to medical workers, the immunocompromised, and people 60 years and older. The Health Ministry estimates that over 6.3 million Israelis (2/3 of the population) have received at least 1 COVID-19 vaccine, and nearly 4.4 million have received 3 doses.
Israel’s cases remain high, which Prime Minister Naftali Bennett partially attributed to the country’s testing efforts; over 5% of the Israeli population is tested for COVID-19 each day.
Despite the preliminary evidence that a fourth dose will not offer sufficient protection against Omicron, Israel will continue to offer it to vulnerable populations, predicting that the variant’s contagions will wane in the coming weeks.
Additionally, “protection from serious morbidity, especially for the elderly population and at-risk population, is still afforded by this vaccine, and therefore I call on people to keep coming to get vaccinated,” Health Ministry director-general Nachman Ash said in a statement.
Advertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
Advertisement
Advertisement